
LINK . SPRINGER . COM {
}
Title:
Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy | Breast Cancer Research
Description:
Introduction Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients. The Mammostrat® test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up. Methods Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal, 23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm2 tissue microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was assigned a Mammostrat® risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and overall survival (OS) were analyzed by marker positivity and risk score. Results Increased Mammostrat® scores were significantly associated with reduced DRFS, RFS and OS in estrogen receptor (ER)-positive breast cancer (P < 0.00001). In multivariate analyses the risk score was independent of conventional risk factors for DRFS, RFS and OS (P < 0.05). In node-negative, tamoxifen-treated patients, 10-year recurrence rates were 7.6 ± 1.5% in the low-risk group versus 20.0 ± 4.4% in the high-risk group. Further, exploratory analyses revealed associations with outcome in both ER-negative and untreated patients. Conclusions This is the fifth independent study providing evidence that Mammostrat® can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context of previous results, these data provide further support for this antibody panel as an aid to patient management in early-stage breast cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).
Matching Content Categories {📚}
- Education
- Health & Fitness
- Science
Content Management System {📝}
What CMS is link.springer.com built with?
Custom-built
No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of link.springer.com audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Link.springer.com Make Money? {💸}
The income method remains a mystery to us.
Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.
Keywords {🔍}
breast, mammostrat, cancer, risk, status, cases, erpositive, patients, score, cancers, article, table, analysis, therapy, adjuvant, drfs, figure, tamoxifen, rfs, survival, google, scholar, data, treated, nodenegative, ernegative, clinical, nodal, pubmed, size, analyses, independent, outcome, study, prognostic, chemotherapy, results, tamoxifentreated, group, significant, recurrence, additional, receptor, file, treatment, distant, high, markers, univariate, lines,
Topics {✒️}
tamoxifen-resistant mcf-7 cells hormone-receptor-positive breast cancer early-stage breast cancer article download pdf conventional tnm staging node-negative breast cancer distant recurrence-free survival compare relapse-free survival er-expressing breast cancer tamoxifen-treated breast cancer breast-conserving surgery cases slightly larger er-positive low-risk breast cancers er-negative breast cancers er-positive breast cancers literature-based meta-analysis tamoxifen-treated breast cancers high-risk group exhibited multivariate regression analysis invasive tumor cells er-negative breast tumors er-negative population versus breast-conservation surgery mammostrat® high-risk group early breast cancer node-negative tumors treated john ms bartlett edinburgh cancer centre node-negative patients treated low-risk population treated er-positive tumors treated node-negative cases treated full size image breast-conserving surgery er-negative cases showed positive breast cancer large conservation series early breast cancers breast cancer specific breakthrough breast cancer tamoxifen-treated cases irrespective breast cancer res full access whilst er-negative cases recurrence-free survival privacy choices/manage cookies primary breast cancer kaplan-meier breast-conserving therapy relapse-free survival
Schema {🗺️}
WebPage:
mainEntity:
headline:Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
description:Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients. The Mammostrat® test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up. Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal, 23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm2 tissue microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was assigned a Mammostrat® risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and overall survival (OS) were analyzed by marker positivity and risk score. Increased Mammostrat® scores were significantly associated with reduced DRFS, RFS and OS in estrogen receptor (ER)-positive breast cancer (P < 0.00001). In multivariate analyses the risk score was independent of conventional risk factors for DRFS, RFS and OS (P < 0.05). In node-negative, tamoxifen-treated patients, 10-year recurrence rates were 7.6 ± 1.5% in the low-risk group versus 20.0 ± 4.4% in the high-risk group. Further, exploratory analyses revealed associations with outcome in both ER-negative and untreated patients. This is the fifth independent study providing evidence that Mammostrat® can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context of previous results, these data provide further support for this antibody panel as an aid to patient management in early-stage breast cancer.
datePublished:2010-07-08T00:00:00Z
dateModified:2010-07-08T00:00:00Z
pageStart:1
pageEnd:11
license:http://creativecommons.org/licenses/by/2.0/
sameAs:https://doi.org/10.1186/bcr2604
keywords:
Breast Cancer
Overall Survival
Tamoxifen
Risk Score
Nodal Status
Cancer Research
Oncology
Surgical Oncology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2604/MediaObjects/13058_2010_2565_Fig1_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2604/MediaObjects/13058_2010_2565_Fig2_HTML.jpg
isPartOf:
name:Breast Cancer Research
issn:
1465-542X
volumeNumber:12
type:
Periodical
PublicationVolume
publisher:
name:BioMed Central
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:John MS Bartlett
affiliation:
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
type:Organization
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Jeremy Thomas
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Douglas T Ross
affiliation:
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
type:Organization
type:Person
name:Robert S Seitz
affiliation:
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
type:Organization
type:Person
name:Brian Z Ring
affiliation:
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
type:Organization
type:Person
name:Rodney A Beck
affiliation:
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
type:Organization
type:Person
name:Hans Christian Pedersen
affiliation:
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Alison Munro
affiliation:
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Ian H Kunkler
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Fiona M Campbell
affiliation:
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Wilma Jack
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Gillian R Kerr
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Laura Johnstone
affiliation:
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:David A Cameron
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Udi Chetty
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
description:Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients. The Mammostrat® test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up. Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal, 23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm2 tissue microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was assigned a Mammostrat® risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and overall survival (OS) were analyzed by marker positivity and risk score. Increased Mammostrat® scores were significantly associated with reduced DRFS, RFS and OS in estrogen receptor (ER)-positive breast cancer (P < 0.00001). In multivariate analyses the risk score was independent of conventional risk factors for DRFS, RFS and OS (P < 0.05). In node-negative, tamoxifen-treated patients, 10-year recurrence rates were 7.6 ± 1.5% in the low-risk group versus 20.0 ± 4.4% in the high-risk group. Further, exploratory analyses revealed associations with outcome in both ER-negative and untreated patients. This is the fifth independent study providing evidence that Mammostrat® can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context of previous results, these data provide further support for this antibody panel as an aid to patient management in early-stage breast cancer.
datePublished:2010-07-08T00:00:00Z
dateModified:2010-07-08T00:00:00Z
pageStart:1
pageEnd:11
license:http://creativecommons.org/licenses/by/2.0/
sameAs:https://doi.org/10.1186/bcr2604
keywords:
Breast Cancer
Overall Survival
Tamoxifen
Risk Score
Nodal Status
Cancer Research
Oncology
Surgical Oncology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2604/MediaObjects/13058_2010_2565_Fig1_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2604/MediaObjects/13058_2010_2565_Fig2_HTML.jpg
isPartOf:
name:Breast Cancer Research
issn:
1465-542X
volumeNumber:12
type:
Periodical
PublicationVolume
publisher:
name:BioMed Central
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:John MS Bartlett
affiliation:
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
type:Organization
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Jeremy Thomas
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Douglas T Ross
affiliation:
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
type:Organization
type:Person
name:Robert S Seitz
affiliation:
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
type:Organization
type:Person
name:Brian Z Ring
affiliation:
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
type:Organization
type:Person
name:Rodney A Beck
affiliation:
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
type:Organization
type:Person
name:Hans Christian Pedersen
affiliation:
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Alison Munro
affiliation:
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Ian H Kunkler
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Fiona M Campbell
affiliation:
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Wilma Jack
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Gillian R Kerr
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Laura Johnstone
affiliation:
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:David A Cameron
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
name:Udi Chetty
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
["Periodical","PublicationVolume"]:
name:Breast Cancer Research
issn:
1465-542X
volumeNumber:12
Organization:
name:BioMed Central
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:John MS Bartlett
affiliation:
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
type:Organization
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
email:[email protected]
name:Jeremy Thomas
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
name:Douglas T Ross
affiliation:
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
type:Organization
name:Robert S Seitz
affiliation:
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
type:Organization
name:Brian Z Ring
affiliation:
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
type:Organization
name:Rodney A Beck
affiliation:
name:Clarient Inc.
address:
name:Clarient Inc., Aliso Viejo, USA
type:PostalAddress
type:Organization
name:Hans Christian Pedersen
affiliation:
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
type:Organization
name:Alison Munro
affiliation:
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
type:Organization
name:Ian H Kunkler
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
name:Fiona M Campbell
affiliation:
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
type:Organization
name:Wilma Jack
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
name:Gillian R Kerr
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
name:Laura Johnstone
affiliation:
name:Edinburgh Cancer Research Centre, Edinburgh University
address:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
type:PostalAddress
type:Organization
name:David A Cameron
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
name:Udi Chetty
affiliation:
name:Western General Hospital
address:
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
type:PostalAddress
type:Organization
PostalAddress:
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
name:Clarient Inc., Aliso Viejo, USA
name:Clarient Inc., Aliso Viejo, USA
name:Clarient Inc., Aliso Viejo, USA
name:Clarient Inc., Aliso Viejo, USA
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
External Links {🔗}(116)
- How much does https://www.springernature.com/gp/authors pull in?
- How much money does https://link.springernature.com/home/ make?
- How much profit does https://order.springer.com/public/cart generate?
- See how much https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research makes per month
- How much revenue does https://breast-cancer-research.biomedcentral.com/about generate?
- How much does https://submission.nature.com/new-submission/13058/3 earn?
- https://doi.org/10.1016%2FS0140-6736%2805%2966544-0's financial summary
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Effects%20of%20chemotherapy%20and%20hormonal%20therapy%20for%20early%20breast%20cancer%20on%20recurrence%20and%2015-year%20survival%3A%20an%20overview%20of%20the%20randomised%20trials&journal=Lancet&doi=10.1016%2FS0140-6736%2805%2966544-0&volume=365&pages=1687-1717&publication_year=2005?
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233540's financial summary
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=The%20interaction%20of%20the%20ER%20with%20ERBB2%20and%20PI3K%20results%20in%20elevated%20levels%20of%20AKT%20and%20p90%28RSK%29%20in%20tamoxifen-resistant%20MCF-7%20cells&journal=Breast%20Cancer%20Res&doi=10.1186%2Fbcr1119&volume=7&publication_year=2005&author=Pancholi%2CS&author=Lykkesfeldt%2CA&author=Johnston%2CSR&author=Dowsett%2CM&author=Martin%2CLA
- Find out how much https://doi.org/10.1056%2FNEJMoa040331 earns monthly
- What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15014181?
- How much does http://scholar.google.com/scholar_lookup?&title=A%20randomized%20trial%20of%20exemestane%20after%20two%20to%20three%20years%20of%20tamoxifen%20therapy%20in%20postmenopausal%20women%20with%20primary%20breast%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa040331&volume=350&publication_year=2004&author=Coombes%2CRC&author=Hall%2CE&author=Gibson%2CLJ&author=Paridaens%2CR&author=Jassem%2CJ&author=Delozier%2CT&author=Jones%2CSE&author=Alvarez%2CI&author=Bertelli%2CG&author=Ortmann%2CO&author=Coates%2CAS&author=Bajetta%2CE&author=Dodwell%2CD&author=Coleman%2CRE&author=Fallowfield%2CLJ&author=Mickiewicz%2CE&author=Andersen%2CJ&author=Lonning%2CPE&author=Cocconi%2CG&author=Stewart%2CA&author=Stuart%2CN&author=Snowdon%2CCF&author=Carpentieri%2CM&author=Massimini%2CG&author=Bliss%2CJM generate monthly?
- Learn about the earnings of https://doi.org/10.1038%2Fsj.bjc.6605231
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19672259 pull in monthly?
- How much income is http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743359 earning monthly?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Tamoxifen%3A%20the%20drug%20that%20came%20in%20from%20the%20cold&journal=Br%20J%20Cancer&doi=10.1038%2Fsj.bjc.6605231&volume=101&pages=875-878&publication_year=2009&author=Hughes-Davies%2CL&author=Caldas%2CC&author=Wishart%2CGC?
- How much revenue does https://doi.org/10.1200%2FJCO.2008.19.5594 generate?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19139426 rake in every month?
- What's the income generated by http://scholar.google.com/scholar_lookup?&title=Up-front%20use%20of%20aromatase%20inhibitors%20as%20adjuvant%20therapy%20for%20breast%20cancer%3A%20the%20emperor%20has%20no%20clothes&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2008.19.5594&volume=27&pages=840-842&publication_year=2009&author=Seruga%2CB&author=Tannock%2CIF each month?
- How much does https://doi.org/10.1002%2Fcncr.23193 pull in?
- How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18072256 make?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Summary%20of%20aromatase%20inhibitor%20clinical%20trials%20in%20postmenopausal%20women%20with%20early%20breast%20cancer&journal=Cancer&doi=10.1002%2Fcncr.23193&volume=112&pages=700-709&publication_year=2008&author=Buzdar%2CAU&author=Coombes%2CRC&author=Goss%2CPE&author=Winer%2CEP bring in?
- Financial intake of https://doi.org/10.1038%2F35021093
- What are the total earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10963602?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Molecular%20portraits%20of%20human%20breast%20tumours&journal=Nature&doi=10.1038%2F35021093&volume=406&pages=747-752&publication_year=2000&author=Perou%2CCM&author=Sorlie%2CT&author=Eisen%2CMB&author=Van%20de%20Rijn%2CM&author=Jeffrey%2CSS&author=Rees%2CCA&author=Pollack%2CJR&author=Ross%2CDT&author=Johnsen%2CH&author=Akslen%2CLA&author=Fluge%2CO&author=Pergamenschikov%2CA&author=Williams%2CC&author=Zhu%2CSX&author=Lonning%2CPE&author=Borresen-Dale%2CAL&author=Brown%2CPO&author=Botstein%2CD?
- What's the monthly money flow for https://doi.org/10.1016%2FS1040-8428%2899%2900034-7?
- What's the financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10532196?
- How profitable is http://scholar.google.com/scholar_lookup?&title=Pathological%20prognostic%20factors%20in%20breast%20cancer&journal=Crit%20Rev%20Oncol%20Hematol&doi=10.1016%2FS1040-8428%2899%2900034-7&volume=31&pages=209-223&publication_year=1999&author=Elston%2CCW&author=Ellis%2CIO&author=Pinder%2CSE?
- What's the income generated by http://scholar.google.com/scholar_lookup?&title=Adjuvant%21%20Version%205.%20Underlying%20data%20and%20assumptions&journal=Breast%20Cancer%20Res%20Treat&volume=82&publication_year=2003&author=Ravdin%2CPM each month?
- How much income is https://doi.org/10.1016%2Fj.ejca.2007.11.012 earning monthly?
- How much income does http://scholar.google.com/scholar_lookup?&title=When%20should%20I%20start%20using%20a%20new%20biomarker%3A%20Focus%20on%20Expression%20arrays%20%28vol%205%2C%20pg%2097%2C%202007%29&journal=Eur%20J%20Cancer&doi=10.1016%2Fj.ejca.2007.11.012&volume=44&pages=326-328&publication_year=2008&author=Desmedt%2CC&author=Sotiriou%2CC have?
- How much profit does https://doi.org/10.1158%2F1078-0432.CCR-07-4756 generate?
- Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18698033
- What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Biological%20processes%20associated%20with%20breast%20cancer%20clinical%20outcome%20depend%20on%20the%20molecular%20subtypes&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-07-4756&volume=14&pages=5158-5165&publication_year=2008&author=Desmedt%2CC&author=Haibe-Kains%2CB&author=Wirapati%2CP&author=Buyse%2CM&author=Larsimont%2CD&author=Bontempi%2CG&author=Delorenzi%2CM&author=Piccart%2CM&author=Sotiriou%2CC?
- See how much https://doi.org/10.1093%2Fjnci%2Fdjj052 makes per month
- What's the financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16478745?
- Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Gene%20expression%20profiling%20in%20breast%20cancer%3A%20understanding%20the%20molecular%20basis%20of%20histologic%20grade%20to%20improve%20prognosis&journal=J%20Natl%20Cancer%20Inst&doi=10.1093%2Fjnci%2Fdjj052&volume=98&pages=262-272&publication_year=2006&author=Sotiriou%2CC&author=Wirapati%2CP&author=Loi%2CS&author=Harris%2CA&author=Fox%2CS&author=Smeds%2CJ&author=Nordgren%2CH&author=Farmer%2CP&author=Praz%2CV&author=Haibe-Kains%2CB&author=Desmedt%2CC&author=Larsimont%2CD&author=Cardoso%2CF&author=Peterse%2CH&author=Nuyten%2CD&author=Buyse%2CM&author=van%20de%20Vijver%2CMJ&author=Bergh%2CJ&author=Piccart%2CMT&author=Delorenzi%2CM
- How much income does https://doi.org/10.1038%2F415530a have?
- http://scholar.google.com/scholar_lookup?&title=Gene%20expression%20profiling%20predicts%20clinical%20outcome%20of%20breast%20cancer&journal=Nature&doi=10.1038%2F415530a&volume=415&pages=530-536&publication_year=2002&author=van%27t%20Veer%2CLJ&author=Dai%2CHY&author=van%20de%20Vijver%2CMJ&author=He%2CYDD&author=Hart%2CAAM&author=Mao%2CM&author=Peterse%2CHL&author=van%20der%20Kooy%2CK&author=Marton%2CMJ&author=Witteveen%2CAT&author=Schreiber%2CGJ&author=Kerkhoven%2CRM&author=Roberts%2CC&author=Linsley%2CPS&author=Bernards%2CR&author=Friend%2CSH's total income per month
- What are the earnings of https://doi.org/10.1056%2FNEJMoa041588?
- What's the income generated by http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15591335 each month?
- How much does http://scholar.google.com/scholar_lookup?&title=A%20multigene%20assay%20to%20predict%20recurrence%20of%20tamoxifen-treated%2C%20node-negative%20breast%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa041588&volume=351&pages=2817-2826&publication_year=2004&author=Paik%2CS&author=Shak%2CS&author=Tang%2CG&author=Kim%2CC&author=Baker%2CJ&author=Cronin%2CM&author=Baehner%2CFL&author=Walker%2CMG&author=Watson%2CD&author=Park%2CT&author=Hiller%2CW&author=Fisher%2CER&author=Wickerham%2CDL&author=Bryant%2CJ&author=Wolmark%2CN bring in each month?
- Earnings of https://doi.org/10.1200%2FJCO.2006.05.6564
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16809728 bring in each month?
- What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Novel%20prognostic%20immunohistochemical%20biomarker%20panel%20for%20estrogen%20receptor-positive%20breast%20cancer&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2006.05.6564&volume=24&pages=3039-3047&publication_year=2006&author=Ring%2CBZ&author=Seitz%2CRS&author=Beck%2CR&author=Shasteen%2CWJ&author=Tarr%2CSM&author=Cheang%2CMCU&author=Yoder%2CBJ&author=Budd%2CGT&author=Nielsen%2CTO&author=Hicks%2CDG&author=Estopinal%2CNC&author=Ross%2CDT?
- Income figures for https://doi.org/10.1158%2F1078-0432.CCR-08-0647
- What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18927301?
- What are the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722068?
- How much income does http://scholar.google.com/scholar_lookup?&title=Chemosensitivity%20and%20stratification%20by%20a%20five%20monoclonal%20andibody%20immunohistochemistry%20test%20in%20the%20NASBP%20B14%20and%20B20%20trials&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-08-0647&volume=14&pages=6602-6609&publication_year=2008&author=Ross%2CDT&author=Kim%2CC-Y&author=Tang%2CG&author=Bohn%2COL&author=Beck%2CRA&author=Ring%2CBZ&author=Seitz%2CRS&author=Paik%2CS&author=Costantino%2CJP&author=Wolmark%2CN have?
- What's the total monthly financial gain of https://doi.org/10.1111%2Fj.1365-2559.2009.03429.x?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19845790 gross monthly?
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=Histological%20grading%20of%20invasive%20breast%20carcinoma%20-%20a%20simplification%20of%20existing%20methods%20in%20a%20large%20conservation%20series%20with%20long-term%20follow-up&journal=Histopathology&doi=10.1111%2Fj.1365-2559.2009.03429.x&volume=55&pages=724-731&publication_year=2009&author=Thomas%2CJS&author=Kerr%2CGR&author=Jack%2CWJL&author=Campbell%2CF&author=Mckay%2CL&author=Pedersen%2CHC&author=Kunkler%2CIH&author=Cameron%2CDA&author=Chetty%2CU&author=Bartlett%2CJMS?
- Get to know what's the income of https://doi.org/10.1093%2Fjnci%2Fdji427
- How much income does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16368942 have?
- Financial intake of http://scholar.google.com/scholar_lookup?&title=Automated%20quantitative%20analysis%20%28AQUA%29%20of%20in%20situ%20protein%20expression%2C%20antibody%20concentration%2C%20and%20prognosis&journal=J%20Natl%20Cancer%20Inst&doi=10.1093%2Fjnci%2Fdji427&volume=97&pages=1808-1815&publication_year=2005&author=McCabe%2CA&author=Dolled-Filhart%2CM&author=Camp%2CRL&author=Rimm%2CDL
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12670887 net monthly?
- What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Quantitative%20analysis%20of%20breast%20cancer%20tissue%20microarrays%20shows%20that%20both%20high%20and%20normal%20levels%20of%20HER2%20expression%20are%20associated%20with%20poor%20outcome&journal=Cancer%20Res&volume=63&pages=1445-1448&publication_year=2003&author=Camp%2CRL&author=Dolled-Filhart%2CM&author=King%2CBL&author=Rimm%2CDL?
- What's the income generated by http://scholar.google.com/scholar_lookup?&title=A%20UK%20NEQAS%20ring%20study%20evaluating%20observer%20variation%20in%20the%20diagnosis%20of%20HER2%20amplification%20using%20the%20Kreatech%20%28TM%29%20HER2%20FISH%20probe&journal=Cancer%20Res&volume=69&publication_year=2009&author=Bartlett%2CJMS&author=Campbell%2CFM&author=Ibrahim%2CM&author=Thomas%2CJ&author=Wenyck%2CI&author=Ellis%2CIO&author=Kay%2CE&author=Connolly%2CY&author=O%27Grady%2CA&author=Cunningham%2CP&author=Barnett%2CS&author=Starczynski%2CJ&author=Miller%2CK each month?
- Income figures for https://doi.org/10.1309%2FAJCPLN78ZQXEMNMA
- Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19095573
- How much money does http://scholar.google.com/scholar_lookup?&title=External%20quality%20assurance%20of%20HER2%20FISH%20and%20ISH%20testing%20three%20years%20of%20the%20UK%20National%20External%20Quality%20Assurance%20Scheme&journal=Am%20J%20Clin%20Pathol&doi=10.1309%2FAJCPLN78ZQXEMNMA&volume=131&pages=106-111&publication_year=2009&author=Bartlett%2CJMS&author=Ibrahim%2CM&author=Jasani%2CB&author=Morgan%2CJM&author=Ellis%2CI&author=Kay%2CE&author=Connolly%2CY&author=Campbell%2CF&author=O%27Grady%2CA&author=Barnett%2CS&author=Miller%2CK generate?
- How much income is https://citation-needed.springer.com/v2/references/10.1186/bcr2604?format=refman&flavour=references earning monthly?
- What's the monthly income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=John%20MS%20Bartlett?
- What's the revenue for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22John%20MS%20Bartlett%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- Find out how much https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jeremy%20Thomas earns monthly
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jeremy%20Thomas%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en pull in?
- Earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Douglas%20T%20Ross
- How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Douglas%20T%20Ross%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in?
- Find out how much https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Robert%20S%20Seitz earns monthly
- What's the revenue for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Robert%20S%20Seitz%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Brian%20Z%20Ring produce monthly?
- Check the income stats for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Brian%20Z%20Ring%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Rodney%20A%20Beck net monthly?
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Rodney%20A%20Beck%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's total income per month
- Check the income stats for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Hans%20Christian%20Pedersen
- What's the income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Hans%20Christian%20Pedersen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- Check the income stats for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alison%20Munro
- How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alison%20Munro%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
- Revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ian%20H%20Kunkler
- How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ian%20H%20Kunkler%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in?
- Revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Fiona%20M%20Campbell
- How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Fiona%20M%20Campbell%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
- How much cash flow does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Wilma%20Jack have monthly?
- Earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Wilma%20Jack%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Gillian%20R%20Kerr generate?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Gillian%20R%20Kerr%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en earn?
- Income figures for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Laura%20Johnstone
- Explore the financials of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Laura%20Johnstone%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=David%20A%20Cameron bring in each month?
- How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22David%20A%20Cameron%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Udi%20Chetty gross monthly?
- Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Udi%20Chetty%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much does https://static-content.springer.com/esm/art%3A10.1186%2Fbcr2604/MediaObjects/13058_2010_2565_MOESM1_ESM.DOC gross monthly?
- How much does https://static-content.springer.com/esm/art%3A10.1186%2Fbcr2604/MediaObjects/13058_2010_2565_MOESM2_ESM.pdf rake in every month?
- Earnings of https://static-content.springer.com/esm/art%3A10.1186%2Fbcr2604/MediaObjects/13058_2010_2565_MOESM3_ESM.pdf
- Earnings of https://static-content.springer.com/esm/art%3A10.1186%2Fbcr2604/MediaObjects/13058_2010_2565_MOESM4_ESM.doc
- What's the profit of https://static-content.springer.com/esm/art%3A10.1186%2Fbcr2604/MediaObjects/13058_2010_2565_MOESM5_ESM.doc?
- See how much http://creativecommons.org/licenses/by/2.0/ makes per month
- What's the profit of https://s100.copyright.com/AppDispatchServlet?title=Mammostrat%C2%AEas%20a%20tool%20to%20stratify%20breast%20cancer%20patients%20at%20risk%20of%20recurrence%20during%20endocrine%20therapy&author=John%20MS%20Bartlett%20et%20al&contentID=10.1186%2Fbcr2604©right=Bartlett%20et%20al.%3B%20licensee%20BioMed%20Central%20Ltd.&publication=1465-542X&publicationDate=2010-07-08&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY?
- See how much https://citation-needed.springer.com/v2/references/10.1186/bcr2604?format=refman&flavour=citation makes per month
- Get to know https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral's earnings
- What's the profit of https://www.springernature.com/gp/products?
- https://www.springernature.com/gp/librarians's financial summary
- Learn about the earnings of https://www.springernature.com/gp/societies
- Earnings of https://www.springernature.com/gp/partners
- How much revenue does https://www.springer.com/ bring in?
- https://www.nature.com/'s financial summary
- What's the monthly income of https://www.biomedcentral.com/?
- https://www.palgrave.com/ income
- See how much https://www.apress.com/ makes per month
- Learn how profitable https://www.springernature.com/gp/legal/ccpa is on a monthly basis
- What's the financial outcome of https://www.springernature.com/gp/info/accessibility?
- What's the revenue for https://support.springernature.com/en/support/home?
- How much does https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations earn?
- How much money does https://www.springernature.com/ generate?
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Clipboard.js
- Prism.js
CDN Services {📦}
- Crossref